此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

PRTH-101 单一疗法 +/- Pembrolizumab 在晚期恶性肿瘤患者中的首次人体研究

2026年9月23日 更新者:Incendia Therapeutics

一项开放标签 1 期剂量递增和扩展研究,调查 PRTH-101 单独或与 Pembrolizumab 联合用于患有晚期或转移性实体瘤的成人的安全性、药代动力学、药效学和活性

The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

研究概览

详细说明

The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

PRTH-101 is a therapeutic antibody that specifically binds to and blocks DDR1, a protein expressed on tumor cells that binds collagen to make a minimally permeable physical barrier that blocks immune cells from interacting with and attacking tumor cells. These "immune cell-excluded" solid tumors are resistant to attack by the immune system (as well as other existing therapies). By disabling DDR1, the collagen fibers lose alignment and loosen, creating gaps in the tumor barrier, thus allowing T-cells to enter and naturally attack the tumor.

The main question[s] it aims to answer are:

  • to evaluate the safety and tolerability of PRTH-101 as mono therapy and in combination with pembrolizumab,
  • to determine the recommended Phase 2 dose as mono therapy and in combination with pembrolizumab,
  • to evaluate anti-tumor activity of PRTH-101 as mono therapy and in combination with pembrolizumab in selected indications

研究类型

介入性

注册 (实际的)

79

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Scottsdale、Arizona、美国、85258
        • Honor Health Research Institute
    • Connecticut
      • New Haven、Connecticut、美国、06511
        • Yale Cancer Center
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Mass General Cancer Center
    • Oregon
      • Portland、Oregon、美国、97213
        • Providence Cancer Institute Franz Clinic
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15232
        • University of Pittsburgh Medical Center Hillman Cancer Center
    • Tennessee
      • Nashville、Tennessee、美国、27232
        • Vanderbilt-Ingram Cancer Center
    • Texas
      • Houston、Texas、美国、77030
        • The University of Texas MD Anderson Cancer Center
      • Houston、Texas、美国、77054
        • NEXT Houston
      • Irving、Texas、美国、75039
        • Next Oncology
      • San Antonio、Texas、美国、78229
        • NEXT Oncology
    • Virginia
      • Fairfax、Virginia、美国、22031
        • Next Oncology

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Subject must be willing and able to read, understand, and sign an Informed Consent Form.

  2. Subject must be age ≥18 years.

  3. Subject has metastatic or advanced, unresectable malignancy and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed at Screening, excluding hepatocellular carcinoma, sarcomas, and gliomas.

  4. Subject has a pathologically documented advanced/unresectable or metastatic cancer that is refractory to or intolerable to or the subject is unwilling or ineligible to receive standard treatment known to confer benefit or for which no standard treatment is available.

  5. Subject must have an Eastern Cooperative Oncology Group performance status (PS) 0-1.

  6. Subject must have a predicted life expectancy of ≥3 months.

  7. Subject must have the following laboratory values (obtained ≤14 days prior to enrollment):

    1. Calculated creatinine clearance must be ≥30 mL/min by Cockcroft-Gault formula calculation
    2. Total bilirubin ≤1.5 × ULN unless has known history of Gilbert's syndrome (in which case, total bilirubin must be ≤3 × ULN)
    3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤1.5 × ULN, or ≤3 x ULN in the presence of liver metastases
    4. Hemoglobin ≥9.0 g/dL
    5. Platelets ≥100 × 109 cells/L 9
    6. Absolute neutrophil count ≥1.5 ×10 cells/L (without the use of hematopoietic growth factors)
    7. Corrected QT interval (QTc) ≤470 milliseconds (as calculated by the Fridericia correction formula)
  8. Women of child-bearing potential (WOCBP) must have a negative pregnancy test within 3 days prior to first administration of PRTH-101.

  9. WOCBP and males with female partners of child-bearing potential must agree to use adequate birth control throughout their participation and for 90 days following the last dose of PRTH-101.

  10. Subject must be willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.

  11. Subject must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines or have archived tissue available (Section 12.3) at enrollment.

    a. Subjects with sites of disease not amenable to biopsy may be considered after discussion with the Sponsor.

  12. The subject is not enrolled in any other clinical trial and is not receiving other therapy directed at their malignancy.

  13. The subject is willing to undergo pre-and post-treatment skin biopsies.

Exclusion Criteria:

  1. Subject has received prior treatment with systemic agents, including, but not limited to, radio-immunoconjugates, antibody-drug conjugates, immune/cytokines, and monoclonal antibodies (e.g., checkpoint inhibitors) within 28 days or five half-lives of the drug, whichever is shorter.

  2. Subject has ongoing toxicity from prior therapy >Grade 1 according to the CTCAE, with the following exceptions. Such exceptions must be assessed by the Investigator (and approved by the Sponsor) as not placing the subject at undue safety risk from participating in this study.

    1. Alopecia, and vitiligo
    2. Grade ≤2 neuropathy
    3. Well-controlled hypo/hyperthyroidism or other endocrinopathies that are well controlled with hormone replacement
  3. Subject has undergone a major surgery (excluding minor procedures e.g., placement of vascular access) <2 months prior to administration of PRTH-101.

  4. Subject has received radiation therapy <28 days prior to administration of PRTH-101.

    a. Exception: limited (e.g., pain palliation) radiation therapy is allowed prior to and during study treatment as long as there are no acute toxicities, and the subject has measurable disease outside the radiation field.

  5. Subject has undergone or is anticipated to undergo organ transplantation including allogeneic or autologous stem-cell transplantation, at any time.

  6. Subject has a diagnosis of immunodeficiency, either primary or acquired.

  7. Subject has received treatment with systemic steroids or any other form of immunosuppressive therapy within 14 days prior to administration of PRTH-101.

    a. Exception: inhaled or topical (to include mouthwash) steroids and adrenal replacement doses are permitted in the absence of active autoimmune disease.

  8. Subject has an active or prior history of autoimmune disease requiring immunosuppressive therapy. Exceptions can be made in discussion with the medical monitor.

  9. Subject has a known severe intolerance to or hypersensitivity reactions to monoclonal antibodies, Fc-bearing proteins (e.g., soluble receptors or other Fc fusion proteins), or IV immunoglobulin preparations; prior history of human antihuman antibody response; known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.

  10. Subject has Central Nervous System (CNS) tumor involvement not definitively treated with surgery or radiation that is active (including evidence of cerebral edema by MRI, or progression from prior imaging study, or has had any requirement for steroids, or clinical symptoms of/from CNS metastases within 28 days prior to study treatment.

  11. Subject has leptomeningeal carcinomatosis, regardless of treatment history.

  12. Subject has current second malignancy at other sites (exceptions: nonmelanomatous skin cancer, adequately treated in situ carcinoma [e.g., cervical], or indolent prostate cancer under observation). A history of other malignancies is allowed as long as subject has been free of recurrence for ≥2 years, or if the subject has been treated with curative intent within the past 2 years and, in the opinion of the Investigator, is unlikely to have a recurrence.

  13. Subject has active and clinically significant bacterial, fungal, or viral infection, including known Hepatitis A, B, or C or HIV (testing not required).

  14. Subject has received live vaccines within the past 30 days (inactivated vaccines are allowed; seasonal vaccines should be up to date >30 days prior to administration of PRTH-101).

  15. Women who are pregnant or breastfeeding.

  16. History of any of the following ≤6 months before first dose:

    a. Congestive heart failure New York Heart Association Grade III or IV b. Unstable angina c. Myocardial infarction d. Unstable symptomatic ischemic heart disease e. Uncontrolled hypertension despite appropriate medical therapy f. Ongoing symptomatic cardiac arrhythmias of > Grade 2 g. Symptomatic cerebrovascular events, or any other serious cardiac condition (e.g., pericardial effusion or restrictive cardiomyopathy); chronic atrial fibrillation on stable anticoagulant therapy is allowed.

  17. Subject has any contraindications to the imaging assessments or other study procedures that subjects will be undergoing.

  18. Subject has any medical or social condition that, in the opinion of the Investigator, might place a subject at increased risk, affect compliance, or confound safety or other clinical study data interpretation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:PRTH-101

Mono-therapy

PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody

实验性的:PRTH-101 with Pembrolizumab

Combo therapy

PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody

PRTH-101 in combination with Pembrolizumab

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Evaluate the Adverse Events (AEs), including Serious Adverse Events (SAEs), that occur in patients treated with PRTH-101
大体时间:Up to 4 years

To evaluate the safety of PRTH-101 as assessed by Adverse Events (AEs), including Serious Adverse Events (SAEs) and Dose Limiting Toxicities (DLTs)

Up to 4 years
Maximum Tolerated Dose
大体时间:Up to 4 years

Maximum dose level not requiring dose de-escalation under Bayesian design rules

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1a and Phase 1b will include the accumulation ratio.

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1a and Phase 1b will include PK maximum concentration (Cmax)

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1a and Phase 1b will include observed serum concentration (Tmax)

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1a and Phase 1b will include last measurable concentration (Clast),

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1a and Phase 1b will include time of last measurable concentration (Tlast,)

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1a and Phase 1b will include area under curve up to the last measurable concentration (AUClast)

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1a and Phase 1b will include, volume of distribution (Vd,)

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1a and Phase 1b will include drug clearance (CL,)

Up to 4 years
Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1a and Phase 1b will include the time required for plasma concentration of a drug to decrease by 50% (t1⁄2.)

Up to 4 years
Anti-tumor activity of PRTH-101 alone and in combination with pembrolizumab
大体时间:Up to 4 years

Best overall response as assessed by iRECIST in 1c

Up to 4 years

次要结果测量

结果测量
措施说明
大体时间
To evaluate the incidence and persistence of anti-PRTH-101 antibody formation and its impact on the PK profile of PRTH-101
大体时间:Up to 4 years

Evaluate anti-drug antibody in serum over multiple timepoints and its impact on the PK profile of PRTH-101

Up to 4 years
To evaluate the incidence and persistence of anti- PRTH-101 antibody formation and its impact on the PK profile of PRTH-101 in combination with pembrolizumab antibody therapy
大体时间:Up to 4 years

Evaluate anti-drug antibody in serum over multiple timepoints and its impact on the PK profile of PRTH-101 in combination with pembrolizumab antibody therapy

Up to 4 years
To evaluate the PK of pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include the accumulation ratio

Up to 4 years
To evaluate the PK of pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include PK maximum concentration (Cmax)

Up to 4 years
To evaluate the PK of pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include observed serum concentration (Tmax)

Up to 4 years
To evaluate the PK of pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include last measurable concentration (Clast)

Up to 4 years
To evaluate the PK of pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include time of last measurable concentration (Tlast)

Up to 4 years
To evaluate the PK of pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include area under curve up to the last measurable concentration (AUClast)

Up to 4 years
To evaluate the PK of pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include volume of distribution (Vd)

Up to 4 years
To evaluate the PK of pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include drug clearance (CL)

Up to 4 years
To evaluate the PK of pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include the time required for plasma concentration of a drug to decrease by 50% (t1⁄2.)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include accumulation ratio

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include PK maximum concentration (Cmax)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include observed serum concentration (Tmax)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include last measurable concentration (Clast)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include time of last measurable concentration (Tlast)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include area under curve up to the last measurable concentration (AUClast)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b as well as Phase 1c will include volume of distribution (Vd)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include drug clearance (CL)

Up to 4 years
To define the PK profile of PRTH-101 together with pembrolizumab
大体时间:Up to 4 years

PK parameters for Phase 1b will include the time required for plasma concentration of a drug to decrease by 50% (t1⁄2.)

Up to 4 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Joseph Paul Eder, MD、Incendia Therapeutics

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年3月3日

初级完成 (实际的)

2026年9月2日

研究完成 (实际的)

2026年9月2日

研究注册日期

首次提交

2023年2月9日

首先提交符合 QC 标准的

2023年2月27日

首次发布 (实际的)

2023年3月3日

研究记录更新

最后更新发布 (实际的)

2026年9月28日

上次提交的符合 QC 标准的更新

2026年9月23日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅